Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 10 of 10 for “"PPV23"”.
-
Pneumococcal vaccine response and aging in human
… 23-valent pneumococcal polysaccharide vaccine (PPV23) has been used clinically since 1983. However, PPV23 is not so effective among old adults with its protective efficacy diminishing with age. We confirmed that young and old adults, who were immunized with PPV23, have comparable pneumococcal …
-
Evaluation of vaccination programs in Australia’s Indigenous and medically at-risk children using record linkage of national immunisation and state health data
… 23-valent pneumococcal polysaccharide vaccine (PPV23) booster against pneumonia hospitalisation in Indigenous children aged 18-60 months who had received PCV dose 3. MAR conditions were ascertained using linked ICD-coded hospitalisations and perinatal data. Coverage of PCV dose 3 was suboptimal …
-
Pneumococcal vaccination in inflammatory rheumatic disease and in splenectomy patients. From antibody response to memory cells.
… least 8 weeks. IgG was determined before PCV and PPV23 and 4-6 weeks after using MFMI and OPA assay. (V) RA patients planned to start methotrexate (MTX) treatment, patients without DMARD and HC were included. Blood was obtained at inclusion, at immunization with PCV13 (after at least 6 weeks on …
-
The health impact and cost-effectiveness of pneumococcal vaccination programs in older Australians
… 23-valent pneumococcal polysaccharide vaccine (PPV23) has been funded under the Australian National Immunisation Program (NIP) since January 2005 for those aged ≥65 years and other younger risk groups. In 2015, a large randomised control trial, Community Acquired Pneumonia immunization Trial in …
-
Investigating the immune system in chrONIC kidney disease - the SONIC study
… (TIV) and 23-valent pneumococcal polysaccharide (PPV23) - in older adults with and without CKD. Despite significantly higher rates of self-reported infections, reductions in humoral responses to vaccination in patients with CKD were subtle, but with evidence of hyporesponsiveness to repeat PPV23 …
-
Health and economic impact of the 13-valent pneumococcal conjugate vaccination program in British Columbia, Canada
… 23-valent pneumococcal polysaccharide vaccine (PPV23) for adults and the 13-valent pneumococcal conjugate vaccine (PCV13) for children. This thesis evaluated changes in health and economic burden from pneumococcal disease following the PCV13 introduction in the infant immunization program in …
-
Population genomics of disease-causing streptococcus pneumonia in Singapore
… pneumococcal vaccines (PCV-7, -10, -13 and PPV23) ranged from 50% to 74%. Further interrogation of the whole genome data classified isolates into 24 major clusters based on their core orthologous genes. As expected, the same serotypes and similar sequence types (STs) clustered together. …
-
Pneumococcal vaccination and respiratory tract infection in older Australian adults
… 23-valent pneumococcal polysaccharide vaccine (PPV23) with 13-valent pneumococcal conjugate vaccine (PCV13) for adults has yielded expected benefits remains uncertain. The impact of pneumococcal vaccination on ARIs and antibiotic use is under explored. This thesis aims to quantify ARI burden and …
-
Hospitalizations Associated with Pneumococcal Infection within the Medicare Population among Vaccinated and Non-vaccinated Patients
… 23-valent pneumococcal polysaccharide vaccine (PPV23). Vaccinated persons were then matched 1:1 on gender and the presence of any comorbidity to unvaccinated persons. Subjects were followed up for 1 year (January 1, 2004 through December 31, 2004). The primary outcomes were pneumonia, pneumonia …
-
O-Acetyltransferase Functionality Mediates Pneumococcal Capsular Diversity
… 23-valent pneumococcal polysaccharide vaccine (PPV23) tar-geted serotype 15B significantly but only slightly more than serotype 15C; therefore, in-clusion of serotype 15B in future conjugate vaccines may not expand serotype 15C. This thesis work primarily suggests that the biological and …